Clinicopathologic and prognostic roles of circular RNA plasmacytoma variant translocation 1 in various cancers

Expert Rev Mol Diagn. 2021 Oct;21(10):1095-1104. doi: 10.1080/14737159.2021.1964959. Epub 2021 Aug 20.

Abstract

Objective: To explore the clinicopathologic and prognostic significance of circular RNA plasmacytoma variant translocation 1 (circPVT1) in various cancers.

Methods: Several databases were searched for eligible studies published before March 01, 2021. The pooled odds ratios (ORs) with 95% confidence interval (95% CI) were calculated to assess the association between circPVT1 expression and prognostic outcomes of tumor including age, gender, clinical stage, tumor size, metastasis and overall survival. Begg's funnel plots and Egger's test were used to evaluate the publication bias. The robustness of our results was assessed using sensitivity analysis.

Results: Ten studies comprising a total of 878 patients with cancer were included in this meta-analysis. The results showed that the high expression of circPVT1 was significantly related to clinical stage (OR=3.44, 95% CI: 2.40-4.94, P<0.05), tumor size (OR=2.29, 95% CI: 1.38-3.79, P<0.05), metastasis (OR=2.97, 95% CI: 2.06-4.28, p<0.05) and overall survival of cancer (OR=3.30, 95% CI: 2.26-4.84, p<0.05), but not associated with age and gender of patients with tumor. No publication bias was found.

Conclusions: High expression of circPVT1 may predict an advanced clinical stage and poor prognosis of tumor, suggesting that circPVT1 may serve as a potential prognostic marker in cancers.

Keywords: CircPVT1; cancers; clinical features; meta-analysis; prognosis.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / genetics
  • Biomarkers, Tumor / metabolism
  • Humans
  • Plasmacytoma* / diagnosis
  • Plasmacytoma* / genetics
  • Prognosis
  • Publication Bias
  • RNA, Circular* / genetics

Substances

  • Biomarkers, Tumor
  • RNA, Circular